Dermata Therapeutics (DRMA) News Today $0.96 +0.03 (+2.98%) Closing price 04:00 PM EasternExtended Trading$0.95 -0.01 (-1.35%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Dermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpointsMarch 28, 2025 | markets.businessinsider.comDermata Therapeutics (NASDAQ:DRMA) Stock Price Up 5.2% - Should You Buy?March 28, 2025 | americanbankingnews.comDermata Therapeutics Shares Surge on Positive Acne Treatment StudyMarch 27, 2025 | marketwatch.comNano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For AcneMarch 27, 2025 | benzinga.comDermata Therapeutics Faces Nasdaq Delisting NoticeMarch 27, 2025 | investing.comDermata shares rise on positive acne treatment trial resultsMarch 27, 2025 | za.investing.comBREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary EndpointsMarch 27, 2025 | prnewswire.comDermata Therapeutics announces last patient visit in Phase 3 acne trialMarch 4, 2025 | markets.businessinsider.comDermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for AcneMarch 4, 2025 | prnewswire.comDermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for HyperhidrosisFebruary 26, 2025 | finanznachrichten.deAPO accepts Dermata’s patent application for DMT410 program for hyperhidrosisFebruary 26, 2025 | markets.businessinsider.comDermata Therapeutics receives notice of acceptance for Australian patentFebruary 26, 2025 | markets.businessinsider.comDermata Therapeutics files to sell 1.94M shares of common stock for holdersJanuary 30, 2025 | markets.businessinsider.comDermata Therapeutics: Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne TreatmentJanuary 29, 2025 | finanznachrichten.deDermata Therapeutics to prices 2M shares at $1.27 in private placementJanuary 23, 2025 | markets.businessinsider.comDermata Therapeutics announces $2.55M private offeringJanuary 22, 2025 | msn.comDermata Therapeutics secures $2.55 million in private placementJanuary 22, 2025 | msn.comDermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)January 21, 2025 | finance.yahoo.comDermata, Revance test new hyperhidrosis treatmentJanuary 21, 2025 | msn.comDermata Therapeutics receives FDA approval for Xyngari proprietary nameDecember 18, 2024 | markets.businessinsider.comDermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 4, 2024 | finance.yahoo.comDermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024November 11, 2024 | globenewswire.comWhy Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving PremarketSeptember 16, 2024 | benzinga.comMaxim cuts Dermata Therapeutics stock target, retains buy on dilution riskAugust 23, 2024 | investing.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | finance.yahoo.com3 Penny Stocks to Watch Now, 8/6/24August 6, 2024 | msn.comDermata Therapeutics (NASDAQ:DRMA) Stock, Short Interest ReportJuly 26, 2024 | benzinga.comDermata Therapeutics (NASDAQ:DRMA) Stock Quotes, Forecast and News SummaryJuly 25, 2024 | benzinga.comActinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer TreatmentJuly 25, 2024 | theglobeandmail.comDermata Therapeutics Shares Are Trading Over 100%: What You Need To KnowJuly 24, 2024 | benzinga.comWhy Is Dermata Therapeutics (DRMA) Stock Up 200% Today?July 24, 2024 | investorplace.comDermata Therapeutics announces warrant exercise and new issuanceMay 19, 2024 | uk.investing.comDRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024May 16, 2024 | investorplace.comDermata Therapeutics, Inc. (DRMAW)February 11, 2024 | ca.finance.yahoo.comPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register NowFebruary 6, 2024 | finance.yahoo.comDermata Therapeutics Inc DRMAFebruary 4, 2024 | morningstar.comDermata to Present at the Emerging Growth Conference on February 7, 2024February 1, 2024 | finance.yahoo.comDermata stock soars on patent issuance, partnership talksJanuary 7, 2024 | msn.comDow Turns Lower; ISM Services PMI Falls In DecemberJanuary 5, 2024 | msn.comWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?January 5, 2024 | msn.comWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?January 5, 2024 | investorplace.comStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion PharmaceuticalsJanuary 4, 2024 | marketwatch.comDermata Therapeutics Shares Surge 120% on Patent Issued in JapanJanuary 4, 2024 | marketwatch.comWhy Dermata Therapeutics Stock Took Off After-HoursJanuary 4, 2024 | msn.comDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of HyperhidrosisJanuary 4, 2024 | finance.yahoo.comDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 21, 2023 | finanznachrichten.deDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and DatesDecember 20, 2023 | benzinga.comDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 20, 2023 | finance.yahoo.comDermata Therapeutics Inc.December 13, 2023 | thestreet.comDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesNovember 16, 2023 | finance.yahoo.com Remove Ads Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address DRMA Media Mentions By Week DRMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRMA News Sentiment▼0.440.61▲Average Medical News Sentiment DRMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRMA Articles This Week▼00▲DRMA Articles Average Week Remove Ads Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CARA News Today LGVN News Today GRCE News Today PMN News Today OVID News Today PASG News Today MURA News Today LSB News Today NAII News Today ANVS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRMA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRMA Stock Free DRMA Stock Alerts